Garvin Kevin L, Miller Ryan E, Gilbert Todd M, White Anthony M, Lyden Elizabeth R
K. L. Garvin, R. E. Miller, T. M. Gilbert, Department of Orthopaedic Surgery and Rehabilitation, Nebraska Medical Center, Omaha, NE, USA A. M. White, UNMC College of Medicine, Nebraska Medical Center, Omaha, NE, USA E. R. Lyden, Department of Biostatistics, Nebraska Medical Center, Omaha, NE, USA.
Clin Orthop Relat Res. 2018 Feb;476(2):345-352. doi: 10.1007/s11999.0000000000000050.
Two-stage reimplantation has consistently yielded high rates of success for patients with chronic prosthetic joint infection, although results more than 5 years after reimplantation are not commonly reported. Numerous factors may contribute to the risk of reinfection, although these factors-as well as the at-risk period after reimplantation-are not well characterized.
QUESTIONS/PURPOSES: (1) What is the risk of reinfection after reimplantation for prosthetic joint infection at a minimum of 5 years? (2) Is the bacteriology of the index infection associated with late reinfection? (3) Is the presence of bacteria at the time of reimplantation associated with late reinfection?
Between 1995 and 2010, we performed 97 two-stage revisions in 93 patients for prosthetic joint infection of the hip or knee, and all are included in this retrospective study. During that time, the indications for this procedure generally were (1) infections occurring more than 3 months after the index arthroplasty; and (2) more acute infections associated with prosthetic loosening or resistant organisms. One patient (1%) was lost to followup; all others have a minimum of 5 years of followup (mean, 11 years; range, 5-20 years) and all living patients have been seen within the last 2 years. Patients were considered free from infection if they did not have pain at rest or constitutional symptoms such as fever, chills, or malaise. The patients' bacteriology and resistance patterns of these organisms were observed with respect to recurrence of infection. Odds ratios and Fisher's exact test were performed to analyze the data. The incidence of reinfection was determined using cumulative incidence methods that considered death as a competing event.
Reinfection occurred in 12 of the 97 joints resulting in implant revision. The estimated 10-year cumulative incidence of infection was 14% (95% confidence interval [CI], 7%-23%) and incidence of infection from the same organism was 5% (95% CI, 1%-11%). Five occurred early or within 2 years and three were resistant pathogens (methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, or vancomycin-resistant Enterococcus). Seven late hematogenous infections occurred and all were > 4 years after reimplantation and involved nonresistant organisms. Three of the five (60%) early infections were caused by resistant bacteria, whereas all seven late infections were caused by different organisms or a combination of different organisms than were isolated in the original infection. The early reinfections were more often caused by resistant organisms, whereas late infections involved different organisms than were isolated in the original infection and none involved resistant organisms. With the numbers available, we found no difference between patients in whom bacteria were detected at the time of reimplantation and those in whom cultures were negative in terms of the risk of reinfection 5 years after reimplantation (18.6% [18 of 97] versus 81.4% [79 of 97], odds ratio 1.56 [95% CI, 0.38-6.44]; p = 0.54); however, with only 93 patients, we may have been underpowered to make this analysis.
In our study, resistant organisms were more often associated with early reinfection, whereas late failures were more commonly associated with new pathogens. We believe the most important finding in our study is that substantial risk of late infection remains even among patients who seemed free from infection 2 years after reimplantation for prosthetic joint infections of the hip or knee. This highlights the importance of educating our patients about the ongoing risk of prosthetic joint infection.
Level III, therapeutic study.
对于慢性人工关节感染患者,两阶段再植入术一直有着较高的成功率,不过再植入术后超过5年的结果通常鲜有报道。尽管再感染风险可能受多种因素影响,但这些因素以及再植入术后的风险期都尚未得到充分描述。
问题/目的:(1)人工关节感染再植入术后至少5年的再感染风险是多少?(2)初次感染的细菌学特征与晚期再感染有关吗?(3)再植入时存在细菌与晚期再感染有关吗?
1995年至2010年间,我们对93例患者的97个髋关节或膝关节人工关节感染进行了两阶段翻修手术,所有病例均纳入本回顾性研究。在此期间,该手术的适应症通常为:(1)初次关节置换术后3个月以上发生的感染;(2)与假体松动或耐药菌相关的更急性感染。1例患者(1%)失访;其他所有患者均至少随访了5年(平均11年;范围5 - 20年),且所有在世患者在过去2年内均接受了检查。如果患者没有静息痛或发热、寒战、不适等全身症状,则认为其未感染。观察患者感染复发时的细菌学特征及这些微生物的耐药模式。采用比值比和Fisher精确检验对数据进行分析。使用将死亡视为竞争事件的累积发病率方法确定再感染的发生率。
97个关节中有12个发生再感染,导致进行了植入物翻修。估计10年累积感染发生率为14%(95%置信区间[CI],7% - 23%),同一微生物引起的感染发生率为5%(95% CI,1% - 11%)。5例发生在早期或2年内,3例为耐药病原体(耐甲氧西林金黄色葡萄球菌、耐甲氧西林表皮葡萄球菌或耐万古霉素肠球菌)。发生了7例晚期血源性感染,均发生在再植入术后4年以上,且涉及非耐药微生物。5例早期感染中有3例(60%)由耐药菌引起,而所有7例晚期感染均由与初次感染中分离出的不同微生物或不同微生物组合引起。早期再感染更常由耐药微生物引起,而晚期感染涉及与初次感染中分离出的不同微生物,且均不涉及耐药微生物。就现有数据而言,我们发现再植入时检测到细菌的患者与培养结果为阴性的患者在再植入术后5年的再感染风险方面没有差异(18.6%[97例中的18例]对81.4%[97例中的79例],比值比1.56[95% CI,0.38 - 6.44];p = 0.54);然而,由于只有93例患者,我们进行此分析的检验效能可能不足。
在我们的研究中,耐药微生物更常与早期再感染相关,而晚期失败更常与新的病原体相关。我们认为本研究中最重要的发现是,即使是在髋关节或膝关节人工关节感染再植入术后2年看似未感染的患者中,晚期感染的风险仍然很大。这凸显了告知患者人工关节感染持续风险的重要性。
III级,治疗性研究。